A preliminary study of individual cognitive behavior therapy for social anxiety disorder in Japanese clinical settings: a single-arm, uncontrolled trial

BMC Research Notes

Eiji Shimizu³  Masaomi Iyo⁴  Akiko Nakagawa³  Michiko Nakazato³  Emi Ito³  Tetsuya Shiraishi⁴  Osamu Kobori²  Kenichi Asano³  Hanae Ibuki¹  Tomomi Kobayashi¹  Mari Tanaka¹  Satoshi Matsuki³  Fumiyo Ohshima³  Naoki Yoshinaga³ 

[1] Department of Cognitive Behavioral Physiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260–8670, Japan;Center for Forensic Mental Health, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan;Research Center for Child Mental Development, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan;Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, 1-8-1 Inohana, Chuo-ku, 260-8670, Japan

关键词: Japanese;    SAD;    Social phobia;    Social anxiety disorder;    CBT;    Cognitive behavioral therapy;   

Others  :  1143404
DOI  :  10.1186/1756-0500-6-74

 received in 2012-11-17, accepted in 2013-02-26,  发布年份 2013

【 摘 要 】

Background

Cognitive behavior therapy (CBT) is regarded as an effective treatment for social anxiety disorder (SAD) in Europe and North America. Individual CBT might be acceptable and effective for patients with SAD even in non-Western cultures; therefore, we conducted a feasibility study of individual CBT for SAD in Japanese clinical settings. We also examined the baseline predictors of outcomes associated with receiving CBT.

Methods

This single-arm trial employed a 14-week individual CBT intervention. The primary outcome was the self-rated Liebowitz Social Anxiety Scale, with secondary measurements of other social anxiety and depressive severity. Assessments were conducted at baseline, after a waiting period before CBT, during CBT, and after CBT.

Results

Of the 19 subjects screened, 15 were eligible for the study and completed the outcome measures at all assessment points. Receiving CBT led to significant improvements in primary and secondary SAD severity (ps < .001). The mean total score on the Liebowitz Social Anxiety Scale improved from 91.8 to 51.7 (before CBT to after CBT), and the within-group effect size at the end-point assessment was large (Cohen’s d = 1.71). After CBT, 73% of participants were judged to be treatment responders, and 40% met the criteria for remission. We found no significant baseline predictors of those outcomes.

Conclusion

Despite several limitations, our treatment—which comprises a 14-week, individual CBT program—seems feasible and may achieve favorable treatment outcomes for SAD in Japanese clinical settings. Further controlled trials are required in order to address the limitations of this study.

Trial registration

UMIN-CTR UMIN000005897

【 授权许可】

   
2013 Yoshinaga et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV-TR. Washington: American Psychiatric Pub; 2000.
• [2]Stein DJ, Ruscio AM, Lee S, Petukhova M, Alonso J, Andrade LHSG, Benjet C, Bromet E, Demyttenaere K, Florescu S, de Girolamo G, de Graaf R, Gureje O, He Y, Hinkov H, Hu C, Iwata N, Karam EG, Lepine J-P, Matschinger H, Oakley Browne M, Posada-Villa J, Sagar R, Williams DR, Kessler RC: Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety 2010, 27:390-403.
• [3]Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM, Katon W, Sherbourne CD: Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005, 43:1164-1170.
• [4]Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC: Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:629-640.
• [5]Sareen J, Jacobi F, Cox BJ, Belik S-L, Clara I, Stein MB: Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 2006, 166:2109-2116.
• [6]Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Zohar J, Hollander E, Kasper S, Möller H-J, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine J-P, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008, 9:248-312.
• [7]Stein DJ, Baldwin DS, Bandelow B, Blanco C, Fontenelle LF, Lee S, Matsunaga H, Osser D, Stein MB, van Ameringen M: A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep 2010, 12:471-477.
• [8]Blanco C, Bragdon LB, Schneier FR, Liebowitz MR: The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol 2013, 16:235-249.
• [9]Hofmann SG, Smits JAJ: Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008, 69:621-632.
• [10]Blomhoff S, Haug TT, Hellström K, Holme I, Humble M, Madsbu HP, Wold JE: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001, 179:23-30.
• [11]Davidson JRT, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004, 61:1005-1013.
• [12]Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ: Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991, 48:938-945.
• [13]Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998, 55:1133-1141.
• [14]Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, Woods SW, Gorman JM: Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry 1998, 155:43-47.
• [15]Lepola U, Bergtholdt B, Lambert B St, Davy KL, Ruggiero L: Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004, 65:222-229.
• [16]Liebowitz MR, Gelenberg AJ, Munjack D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005, 62:190-198.
• [17]Ono Y, Furukawa TA, Shimizu E, Okamoto Y, Nakagawa A, Fujisawa D, Nakagawa A, Ishii T, Nakajima S: Current status of research on cognitive therapy/cognitive behavior therapy in Japan. Psychiatry Clin Neurosci 2011, 65:121-129.
• [18]Prince R, Tcheng-Laroche F: Culture-bound syndromes and international disease classifications. Cult Med Psychiatry 1987, 11:3-52.
• [19]Russell JG: Anxiety disorders in Japan: a review of the Japanese literature on shinkeishitsu and taijinkyofusho. Cult Med Psychiatry 1989, 13:391-403.
• [20]Kleinknecht RA, Dinnel DL, Kleinknecht EE, Hiruma N, Harada N: Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin kyofusho. J Anxiety Disord 1997, 11:157-177.
• [21]Suzuki K, Takei N, Kawai M, Minabe Y, Mori N: Is taijin kyofusho a culture-bound syndrome? Am J Psychiatry 2003, 160:1358.
• [22]Choy Y, Schneier FR, Heimberg RG, Oh K-S, Liebowitz MR: Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder. Depress Anxiety 2008, 25:230-240.
• [23]Hofmann SG, Anu Asnaani MA, Hinton DE: Cultural aspects in social anxiety and social anxiety disorder. Depress Anxiety 2010, 27:1117-1127.
• [24]Stein DJ: Social anxiety disorder in the West and in the East. Ann Clin Psychiatry 2009, 21:109-117.
• [25]Chen J, Nakano Y, Ietzugu T, Ogawa S, Funayama T, Watanabe N, Noda Y, Furukawa TA: Group cognitive behavior therapy for Japanese patients with social anxiety disorder: preliminary outcomes and their predictors. BMC Psychiatry 2007, 7:69. BioMed Central Full Text
• [26]Chen J, Furukawa TA, Nakano Y, Ietsugu T, Ogawa S, Funayama T, Watanabe N, Noda Y, Rapee RM: Video feedback with peer ratings in naturalistic anxiety-provoking situations for social anxiety disorder: preliminary report. J Behav Ther Exp Psychiatry 2010, 41:6-10.
• [27]Watanabe N, Furukawa TA, Chen J, Kinoshita Y, Nakano Y, Ogawa S, Funayama T, Ietsugu T, Noda Y: Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study. BMC Psychiatry 2010, 10:81. BioMed Central Full Text
• [28]Mörtberg E, Clark DM, Sundin O, Aberg Wistedt A: Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand 2007, 115:142-154.
• [29]Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM: Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther 2003, 41:991-1007.
• [30]Liebowitz MR: Social phobia. Mod Probl Pharmacopsychiatry 1987, 22:141-173.
• [31]Raj BA, Sheehan DV: Social anxiety disorder. Med Clin North Am 2001, 85:711-733.
• [32]Sugawara N, Yasui-Furukori N, Kaneda A, Sato Y, Tsuchimine S, Fujii A, Danjo K, Takahashi I, Matsuzaka M, Kaneko S: Factor structure of the Liebowitz Social Anxiety Scale in community-dwelling subjects in Japan. Psychiatry Clin Neurosci 2012, 66:525-528.
• [33]Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E: The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord 2001, 31:5-17.
• [34]First MB, Gibbon M: User’s Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version. Washington: American Psychiatric Pub; 1997.
• [35]First MB, Gibbon M: User’s Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders: SCID-II. Washington: American Psychiatric Pub; 1997.
• [36]Clark DM, Wells A: A cognitive model of social phobia. In Social Phobia: Diagnosis, Assessment, and Treatment. Edited by Heimberg RG, Liebowitz M, Hope DA, Schneier FR. New York: Guilford Press; 1995:69-93.
• [37]Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003, 71:1058-1067.
• [38]Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol 2006, 74:568-578.
• [39]Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM: Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry 2011, 68:692-700.
• [40]Blackburn I-M, James IA, Milne DL, Baker C, Standart S, Garland A, Reichelt FK: The Revised Cognitive Therapy Scale (CTS-R): psychometric properties. Behav Cogn Psychother 2001, 29:431-446.
• [41]Mattick RP, Clarke JC: Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998, 36:455-470.
• [42]Watson D, Friend R: Measurement of social-evaluative anxiety. J Consult Clin Psychol 1969, 33:448-457.
• [43]Marks IM, Mathews AM: Brief standard self-rating for phobic patients. Behav Res Ther 1979, 17:263-267.
• [44]Asakura S, Inoue S, Sasaki F, Sasaki Y, Kitagawa N, Inoue T, Denda K, Ito M, Matsubara R, Koyama T: Reliability and validity of the Japanese version of the Liebowitz Social Anxiety Scale. Seishin Igaku (Clinical Psychiatry) 2002, 44:1077-1084.
• [45]Kanai Y, Sasakawa S, Chen J, Suzuki S, Shimada H, Sakano Y: Development and validation of the Japanese version of Social Phobia Scale and Social Interaction Anxiety Scale. Shingshin-Igaku (Jpn J Psychosom Med) 2004, 44:841-850.
• [46]Ishikawa R, Sasaki K, Fukui I: Standardization of Japanese version of FNE and SADS. Koudou Ryouhou Kenkyu (Jap J Behav Ther) 1992, 18:10-17.
• [47]Mohr DC, Spring B, Freedland KE, Beckner V, Arean P, Hollon SD, Ockene J, Kaplan R: The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 2009, 78:275-284.
• [48]Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ: What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006, 67:1428-1434.
• [49]Cohen J: Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale: Erlbaum; 1988.
• [50]Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, Goetz D: The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med 2001, 31:1025-1035.
• [51]Marom S, Gilboa-Schechtman E, Aderka IM, Weizman A, Hermesh H: Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy. Depress Anxiety 2009, 26:289-300.
• [52]Chambless DL, Tran GQ, Glass CR: Predictors of response to cognitive-behavioral group therapy for social phobia. J Anxiety Disord 1997, 11:221-240.
• [53]Blanco C, Schneier FR, Schmidt A, Blanco-Jerez C-R, Marshall RD, Sánchez-Lacay A, Liebowitz MR: Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 2003, 18:29-40.
• [54]Van Ameringen M, Mancini C, Pipe B, Bennett M: Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr 2004, 9:753-762.
• [55]Stein MB, Stein DJ: Social anxiety disorder. Lancet 2008, 371:1115-1125.